What is Eterna Therapeutics Debt-to-Equity?
Eterna Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.22 Mil. Eterna Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $39.63 Mil. Eterna Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $2.23 Mil.
Eterna Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 18.74.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Eterna Therapeutics's Debt-to-Equity or its related term are showing as below:
ERNA'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1 Med: 0.24 Max: 18.74
Current: 18.74
During the past 4 years, the highest Debt-to-Equity Ratio of Eterna Therapeutics was 18.74. The lowest was 0.10. And the median was 0.24.
Eterna Therapeutics Debt-to-Equity Historical Data
The historical data trend for Eterna Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eterna Therapeutics Debt-to-Equity Chart
|
Eterna Therapeutics Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
0.38 |
0.11 |
0.10 |
18.74 |
|
Eterna Therapeutics Quarterly Data
|
|
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
0.10 |
0.14 |
9.09 |
11.12 |
18.74 |
Competitive Comparison of Eterna Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Eterna Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eterna Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eterna Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Eterna Therapeutics's Debt-to-Equity falls into.
Eterna Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Eterna Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Eterna Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eterna Therapeutics (Eterna Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
Executives
| Dorothy J Clarke |
director |
C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141 |
| Charles Cherington |
10 percent owner |
ONE BOW STREET, CAMBRIDGE MA 02138 |
| Brant Binder |
director |
C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066 |
| Richard W Wagner |
director |
C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451 |
| Curtis W Huft |
10 percent owner |
4510 LAMESA HWY, SNYDER TX 79549 |
| Freebird Partners Lp |
10 percent owner |
2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056 |
| Freebird Investments Llc |
10 percent owner |
2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056 |
| John D Halpern |
10 percent owner |
|
| Nicholas Jason Singer |
director |
1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131 |
| William A. Wexler |
director |
12 GILL STREET, SUITE 4650, WOBURN MA 01801 |
| Gregory Fiore |
director |
10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121 |
| Andrew C. Jackson |
officer: Chief Financial Officer |
11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130 |
| Matthew Angel |
officer: Interim President and CEO |
10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127 |
| Heather B Redman |
director |
TWO NORTH NINTH STREET, ALLENTOWN PA 18101 |
| Erin S. Enright |
director |
666 PLAINSBORO ROAD, PLAINSBORO NJ 08536 |
Eterna Therapeutics (Eterna Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ERNA has been successfully added to your